ECSP066517A - Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Info

Publication number
ECSP066517A
ECSP066517A EC2006006517A ECSP066517A ECSP066517A EC SP066517 A ECSP066517 A EC SP066517A EC 2006006517 A EC2006006517 A EC 2006006517A EC SP066517 A ECSP066517 A EC SP066517A EC SP066517 A ECSP066517 A EC SP066517A
Authority
EC
Ecuador
Prior art keywords
piridin
triazol
chlorophenyl
trifluorometil
bencil
Prior art date
Application number
EC2006006517A
Other languages
English (en)
Inventor
Susan Marie Reutzel-Edens
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Shella Lenyonga Tameze
Carsten Timpe
Carsten Weber
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP066517A publication Critical patent/ECSP066517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1H-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona, composiciones de las mismas, intermediarios de las mismas, métodos de uso de las mismas, procesos para elaborar las mismas, y procesos para elaborar intermediarios de las mismas.
EC2006006517A 2003-10-24 2006-04-21 Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona ECSP066517A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
ECSP066517A true ECSP066517A (es) 2006-10-10

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006517A ECSP066517A (es) 2003-10-24 2006-04-21 Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001311A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ545917A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2121610T1 (sl) 2006-12-20 2014-08-29 Eli Lilly & Company Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP4110335B1 (en) 2020-02-25 2025-10-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
HK1045507A1 (zh) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated C-jun n-末端激酶(jnk)及其他蛋白质激酶的抑制物
JP2003513095A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド タキキニン受容体アンタゴニストの多形
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
DK1501809T3 (da) * 2002-04-26 2008-05-13 Lilly Co Eli Trizolderivater som tachykininreceptorantagonister

Also Published As

Publication number Publication date
NO20062371L (no) 2006-05-24
NZ580480A (en) 2010-02-26
AU2004285855B8 (en) 2011-04-28
NZ545917A (en) 2009-11-27
IL174926A0 (en) 2006-08-20
PT1675846E (pt) 2010-04-20
UA82901C2 (en) 2008-05-26
EA008881B1 (ru) 2007-08-31
MA28329A1 (fr) 2006-12-01
TW200524906A (en) 2005-08-01
DK1675846T3 (da) 2010-05-31
US20070078166A1 (en) 2007-04-05
EA200600829A1 (ru) 2006-08-25
PE20050481A1 (es) 2005-09-20
KR100848407B1 (ko) 2008-07-28
JP2007509143A (ja) 2007-04-12
CA2542140C (en) 2012-05-29
JP4959336B2 (ja) 2012-06-20
ES2340772T3 (es) 2010-06-09
ATE462700T1 (de) 2010-04-15
CN1863791B (zh) 2011-12-07
CL2009001311A1 (es) 2009-10-02
CR8353A (es) 2006-06-06
AR046131A1 (es) 2005-11-23
CA2542140A1 (en) 2005-05-12
AU2004285855A1 (en) 2005-05-12
WO2005042515A1 (en) 2005-05-12
MY157375A (en) 2016-06-15
CN1863791A (zh) 2006-11-15
CL2009001310A1 (es) 2009-12-04
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
ZA200603234B (en) 2007-07-25
AU2004285855B2 (en) 2010-12-23
NO335090B1 (no) 2014-09-08
BRPI0415010A (pt) 2006-11-07
BRPI0415010B1 (pt) 2019-07-09
HRP20100207T1 (hr) 2010-05-31
KR20060061388A (ko) 2006-06-07
BRPI0415010A8 (pt) 2018-05-08
BRPI0415010B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CO4940418A1 (es) Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CR8291A (es) Formas polimorficas 3-(4-amino-1-oxo-1,3 dihidro -isoindol-2-il)-piperidin-2, 6-diona
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
NO20055135L (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
CY1108366T1 (el) Βενζοσουλφονικο αλας της 7-(2-(4-(3-τριφθορομεθυλ-φαινυλ-1,2,3,6-τετραϋδρο-πυριδ-1-υλ)αιθυλ)ισοκινολινης, η παρασκευη του και η χρηση του στη φαρμακευτικη αγωγη
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
MXPA05011962A (es) Oxiarenos substituidos.
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
NO20062629L (no) Oksazolderivater av tetrackliner
BRPI0516200A (pt) forma cristalina do cloridrato de (3-ciano-1h-indol-7-il)-[4-(4-fluorfenetril)piperazin-1-i l]metanona
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
ECSP109874A (es) Nuevos compuestos 892
WO2006124865A3 (en) Biaryls derivatives useful as modulators of ion channels